Ultragenyx Pharmaceutical Inc. (RARE) Return on equity 2016–2024
Ultragenyx Pharmaceutical Inc. (RARE) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-223.1%FY2024 · since FY2016: -51.9% → -223.1%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2024 | -223.1% | -2.4 pp |
| FY2023 | -220.7% | -19.8 pp |
| FY2022 | -201.0% | -151.8 pp |
| FY2021 | -49.2% | -33.1 pp |
| FY2020 | -16.2% | +45.4 pp |
| FY2019 | -61.6% | -29.1 pp |
| FY2018 | -32.5% | +46.3 pp |
| FY2017 | -78.8% | -26.9 pp |
| FY2016 | -51.9% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice